The company says the new application covers engineered cells that release GLP-1, GIP, GLP-2 and other peptides. It's investigational and not FDA approved.
Recap by typeshit. Post by @FibroBiologics on X.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Medical Xpress reports late stage results for Lilly's triple-action shot in patients with type 2 diabetes.
The post says four in ten patients drop GLP-1 drugs within a year over side effects, and pharma is turning to amylin-based shots as the next step.
Loading…